Application experience of enzalumide in mCRPC patients with cardiopulmonary disease / 中华泌尿外科杂志
Chinese Journal of Urology
;
(12): 40-42, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-933146
ABSTRACT
Metastatic castration-resistant prostate cancer (mCRPC) is the inevitable form of most prostate cancers after endocrine therapy, and conventional drugs are not effective at this time.In this case, an elderly mCRPC patient with cardiopulmonary diseases admitted to the First Hospital of Shanxi Medical University in August 2020 was selected. After the failure of traditional endocrine therapy, enzalumide+ ADT regimen was adopted, and the patient's blood PSA was significantly reduced without cardiopulmonary adverse events.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Urology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS